Dr. Hamidi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-2800Fax+1 214-645-2808
Summary
- Dr. Oksana Hamidi is an endocrinologist in Dallas, TX and is affiliated with University of Texas Southwestern Medical Center. She received her medical degree from Chicago College of Osteopathic Medicine and has been in practice 5 years. She specializes in adrenal disease, diabetes, lipid metabolism, and pituitary disorders & neuroendocrinology and is experienced in pituitary disease, adrenal disease, and neuroendocrinology.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 2015 - 2018
- Cook County Health and Hospitals SystemResidency, Internal Medicine, 2012 - 2015
- Chicago College of Osteopathic Medicine at Midwestern UniversityClass of 2012
Certifications & Licensure
- TX State License 2018 - 2026
- MN State License 2015 - 2018
- IL State License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 5 citationsEuropean Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency.Felix Beuschlein, Tobias Else, Irina Bancos, Stefanie Hahner, Oksana Hamidi
European Journal of Endocrinology. 2024-05-02 - 29 citationsClinical course of adrenal myelolipoma: a long‐term longitudinal follow‐up studyOksana Hamidi, Ram Narayan Raman, Natalia Lazik, Nicole M. Iñiguez-Ariza, Travis J. McKenzie
Clinical Endocrinology. 2020-04-10 - 199 citationsMalignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.Oksana Hamidi, William F. Young, Nicole M. Iñiguez-Ariza, Nana Esi Kittah, Lucinda Gruber
The Journal of Clinical Endocrinology and Metabolism. 2017-09-01
Press Mentions
- Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024May 10th, 2024
- CAH Treatment 'Struggle' Points to Unmet NeedMay 16th, 2024
- UTSW Research: Female Sex Hormones, Adrenal Hyperplasia, and MoreJuly 3rd, 2024
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: